CLYYF Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Celyad Oncology SA

Watchlist Manager

Watchlist

Price: 0.28 USD

Market Cap: $11.6m

	Celyad Oncology SA OTC:CLYYF	BE
K	Kyowa Leather Cloth Co Ltd TSE:3553	JP
S	Sixt SE XHAM:SIX3	DE
	Kinarus Therapeutics Holding AG SIX:CURN	CH
P	PC Direct Inc KOSDAQ:051380	KR
	Iren SpA MIL:IRE	IT
J	J B Hunt Transport Services Inc LSE:0J71	US
H	Hertz Lithium Inc OTC:HZLIF	CA
	Kymera Therapeutics Inc NASDAQ:KYMR	US

Profitability Summary

Celyad Oncology SA's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

62%

Strong 3Y Average Gross Margin

67%

Negative Operating Margin

-6 852%

Negative 3Y Average Operating Margin

-6 729%

Operating Margin is Increasing

-69 386% > -6 852%

Exceptional Net Margin

3 952%

Negative 3Y Average Net Margin

-4 340%

Net Margin is Increasing

-69 589% > 3 952%

Negative Free Cash Flow Margin

-32 857%

Negative 3Y Average Free Cash Flow Margin

-13 850%

Free Cash Flow Margin is Increasing

-46 361% > -32 857%

Exceptional ROE

56%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-125%

ROIC is Increasing

-132% > -44%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.